THE SHORT VERSION
- GLP-1 receptor agonists (and related medicines) are prescription-only in the UK. They can help some adults with obesity or related health risks when prescribed after a proper assessment — but they are not suitable for everyone.
What GLP-1 medicines are used for in the UK
Licensed uses include weight management and, for some products, type 2 diabetes. Mounjaro (tirzepatide) and Wegovy (semaglutide) are the names most UK patients encounter when researching private or NHS access.
Safety-first expectations
Side effects are common, especially during dose increases. Serious risks are rarer but important — including pancreatitis and severe dehydration from persistent vomiting.
Sources you can check
- MHRA GLP-1 medicines safety guidance
- MHRA Yellow Card scheme
- NICE TA1026 on tirzepatide (Mounjaro)
- NICE TA875 on semaglutide (Wegovy)
Editorial presentation updated 24 October 2026. This is general information, not individual medical advice or a claim of independent clinical review. Read the linked source and the leaflet supplied with your medicine for the full context. Suggest a correction.